144 related articles for article (PubMed ID: 16521658)
21. Some key points emerging from the COX-2 controversy.
Urquhart J
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):145-7. PubMed ID: 15654723
[No Abstract] [Full Text] [Related]
22. Postsurgical safety of opioid-sparing cyclooxygenase-2 inhibitors.
Babul N; Sloan P; Lipman AG
Anesthesiology; 2006 Feb; 104(2):375; author reply 376. PubMed ID: 16436859
[No Abstract] [Full Text] [Related]
23. Cardiovascular complications of COX2 selective inhibitors cause considerable concern.
Hedner T; Himmelmann A
Blood Press; 2004; 13(5):260-1. PubMed ID: 15545147
[No Abstract] [Full Text] [Related]
24. [Overestimated].
Höer A; Häussler B
Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
[No Abstract] [Full Text] [Related]
25. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
van der Veen WJ; van der Werf GT
Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
[TBL] [Abstract][Full Text] [Related]
26. VICTOR spoiled?
Goldberg RM; Bertagnolli MM
J Clin Oncol; 2010 Oct; 28(30):4546-8. PubMed ID: 20837951
[No Abstract] [Full Text] [Related]
27. How specific are "target-specific" drugs? Celecoxib as a case in point.
Sadée W; Bohn L
Mol Interv; 2006 Aug; 6(4):196-8. PubMed ID: 16960141
[TBL] [Abstract][Full Text] [Related]
28. Evaluating drug effects in the post-Vioxx world: there must be a better way.
Avorn J
Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
[No Abstract] [Full Text] [Related]
29. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
30. [Cyclooxygenase inhibitors: a never ending story?].
Macrì R; Manfredi C
G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
[No Abstract] [Full Text] [Related]
31. Vioxx should be allowed back on the market advises expert panel.
Sibbald B
CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435
[No Abstract] [Full Text] [Related]
32. Life after Vioxx.
Underwood A
Newsweek; 2005 Jan; 145(5):40-1. PubMed ID: 17896720
[No Abstract] [Full Text] [Related]
33. International regulatory activity restricting COX-2 inhibitor use and deaths due to gastrointestinal haemorrhage and myocardial infarction.
Metcalfe C; Wheeler BW; Gunnell D; Martin RM
Pharmacoepidemiol Drug Saf; 2010 Aug; 19(8):778-85. PubMed ID: 20680998
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular effects of cyclooxygenase-2 inhibitors.
Brophy JM
Curr Opin Gastroenterol; 2007 Nov; 23(6):617-24. PubMed ID: 17906437
[TBL] [Abstract][Full Text] [Related]
35. Use of cox-2 inhibitors in patients with retinal venous occlusive disease.
Recchia FM; Chen E; Li C; Maguluri S
Retina; 2008 Jan; 28(1):134-7. PubMed ID: 18185149
[TBL] [Abstract][Full Text] [Related]
36. Rofecoxib in mild cognitive impairment.
Ownby RL
Curr Psychiatry Rep; 2006 Feb; 8(1):9-10. PubMed ID: 16513035
[No Abstract] [Full Text] [Related]
37. Successful treatment of cystoid macular edema with valdecoxib.
Chan VC; Liu DT; Lee VY; Lam PT
J Cataract Refract Surg; 2007 Nov; 33(11):1837-8; author reply 1838. PubMed ID: 17964375
[No Abstract] [Full Text] [Related]
38. Ocular adverse effects associated with cyclooxygenase-2 inhibitors.
Fraunfelder FW; Solomon J; Mehelas TJ
Arch Ophthalmol; 2006 Feb; 124(2):277-9. PubMed ID: 16476901
[No Abstract] [Full Text] [Related]
39. More bad news about anti-inflammatory agents.
Haller C
J Med Toxicol; 2005 Dec; 1(1):36-7. PubMed ID: 18072102
[No Abstract] [Full Text] [Related]
40. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
